LTR Pharma Ltd Total Assets
LTR Pharma Ltd total assets. Based on the latest financial reports, LTR Pharma Ltd (LTP) holds total assets worth AU$27.32 Million AUD (≈ $19.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LTP market cap for the company's overall valuation and market capitalisation.
Total Assets of LTR Pharma Ltd (2021–2025)
Total assets of LTR Pharma Ltd from 2021 to 2025. This chart illustrates how LTR Pharma Ltd's total assets have evolved over time, based on quarterly financial data. See LTR Pharma Ltd share price for real-time trading data and today's change.
LTR Pharma Ltd - Asset Composition Analysis
LTR Pharma Ltd Total Assets Breakdown (June 2025)
LTR Pharma Ltd total assets breakdown as of June 2025. LTR Pharma Ltd's total assets of AU$27.32 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 98.8% |
| Accounts Receivable | AU$4.40K | 0.0% |
| Inventory | AU$19.63K | 0.1% |
| Property, Plant & Equipment | AU$12.60K | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how LTR Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore LTP current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LTR Pharma Ltd's current assets represent 99.6% of total assets in 2025, an increase from 34.6% in 2021.
- Cash Position: Cash and equivalents constituted 98.8% of total assets in 2025, up from 34.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 0.1% of total assets.
LTR Pharma Ltd Competitors by Total Assets
Key competitors of LTR Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.71 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
LTR Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 57.47 | 79.99 | 19.23 |
| Quick Ratio | 57.42 | 79.99 | 19.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$25.85 Million | AU$34.23 Million | AU$5.98 Million |
LTR Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between LTR Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 1.88 |
| Asset Growth Rate (YoY) | 856.1% |
| Total Assets | AU$32.21 Million |
| Market Capitalization | $60.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values LTR Pharma Ltd's assets above their book value (1.88x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: LTR Pharma Ltd's assets grew by 856.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LTR Pharma Ltd (2021–2025)
The table below shows the annual total assets of LTR Pharma Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$32.21 Million ≈ $22.79 Million |
+856.07% |
| 2024-06-30 | AU$3.37 Million ≈ $2.38 Million |
+60.92% |
| 2023-06-30 | AU$2.09 Million ≈ $1.48 Million |
-6.75% |
| 2022-06-30 | AU$2.25 Million ≈ $1.59 Million |
+431.20% |
| 2021-06-30 | AU$422.70K ≈ $299.09K |
-- |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more